Novo Nordisk and Eli Lilly Present Unverified Aging Clock Findings
Novo Nordisk and Eli Lilly claim their weight-loss drugs may slow aging clocks, but the data remains unverified and inconclusive.
Novo and Lilly's findings on aging clocks are not peer-reviewed.
Current evidence does not support GLP-1 drugs for anti-aging in healthy individuals.
FDA warns against unapproved GLP-1 drugs due to safety concerns.
At a recent conference in Boston, Novo Nordisk and Eli Lilly announced findings suggesting that their GLP-1 weight-loss medications, Ozempic and Zepbound, may slow molecular aging clocks. However, these claims are based on unverified data, with Novo's analysis not undergoing peer review and Lilly's results being presented in a conference setting rather than published in a scientific journal.
The concept of aging clocks involves mathematical models that estimate biological age based on blood proteins or DNA markers. While Novo's analysis indicated that participants taking semaglutide had a biological age approximately two to four years younger than those on a placebo, the authors cautioned that these findings do not equate to actual health benefits or longevity. The drugs remain approved only for specific medical conditions, including type 2 diabetes and obesity, and not for anti-aging purposes.
Novo's research involved a comprehensive analysis of blood samples from over 10,000 participants across multiple trials, revealing reductions in biological age across various organs. In contrast, Lilly's smaller study utilized epigenetic clocks to assess age reduction, but both studies lack robust evidence linking these findings to improved health outcomes. Experts have pointed out that while the results are intriguing, they do not provide sufficient justification for using these drugs for longevity.
The implications of these findings are significant for patients currently prescribed GLP-1 medications. While the data may offer some reassurance regarding the drugs' effects, they do not alter treatment protocols. The primary concern lies with healthy individuals who may seek these drugs for anti-aging benefits, as insurance typically does not cover such uses. The FDA has issued warnings about the dangers of unapproved GLP-1 drugs, which may contain harmful ingredients or incorrect dosages.
Looking ahead, further research is necessary to establish the validity of these findings. Upcoming trials, including a large-scale study led by UT Health San Antonio set to begin in 2027, aim to explore the effects of GLP-1 drugs on aging in older adults. Until then, experts advise caution, emphasizing that anyone considering these medications should consult healthcare professionals before making any changes to their treatment plans.
